Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration

被引:36
作者
Gaig, Carles [2 ]
Ezquerra, Mario [2 ]
Marti, Maria Jose [2 ]
Valldeoriola, Francesc [2 ]
Munoz, Esteban [2 ]
Llado, Albert [2 ,3 ]
Rey, Maria Jesus [4 ]
Cardozo, Adriana [4 ]
Molinuevo, Jose Luis [2 ,3 ]
Tolosa, Eduardo [1 ,2 ]
机构
[1] Hosp Clin Barcelona, Neurol Serv, ICN, Dept Neurol,Parkinsons Dis & Movement Disorders U, E-08036 Barcelona, Spain
[2] Univ Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Ctr Invest Biomed Red Enfermedades Neurodegenerat, E-08036 Barcelona, Spain
[3] Hosp Clin Barcelona, ICN, Dept Neurol, Alzheimers Dis & Other Cognit Disorders Unit, E-08036 Barcelona, Spain
[4] Univ Barcelona, Hosp Clin Barcelona, Neurol Tissue Bank, E-08036 Barcelona, Spain
关键词
LRRK2 G2019S mutation; LRRK2 R1441G mutation; Parkinson's disease; dementia with Lewy bodies; frontotemporal lobar degeneration; non-specific nigral degeneration; neuropathology;
D O I
10.1016/j.jns.2008.02.010
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: The neuropathology associated with LRRK2 mutations is heterogeneous but Lewy body (LB) type pathology is the most common substrate encountered. While the prevalence of LRRK2 mutations has been extensively studied in Parkinson's disease (PD), limited information is available on the frequency of LRRK2 mutations in dementia with Lewy bodies (DLB) and in other pathological conditions associated with these mutations, such as non-specific nigral degeneration without LB, tau-immunopositive neurofibrillary tangle pathology, and ubiquitin-positive neuronal inclusions resembling those observed in a subtype of frontotemporal lobar degeneration (FTLD-U). Objective: To further investigate the neuropathology associated with LRRK2 mutations. Methods: We have screened for the LRRK2 G2019S and codon-1441 (R1441G/C/H) mutations in 110 cases from a Spanish Brain Bank, which include: 66 synucleinopathies (33 PD, 25 DLB and 8 multiple system atrophy cases), 29 tauopathies (21 progressive supranuclear palsy, 3 corticobasal degeneration and 5 tau-positive FTLD cases), 3 cases of non-specific nigral degeneration and 12 tau-negative FTLD (9 FTLD-U and 3 dementia lacking distinctive histology cases). Results: The G2019S mutation was found in two cases: One case had a clinical and pathological diagnosis of PD and the other suffered from typical PD and on neuropathological examination had non-specific nigral degeneration without LB. A synonymous variant (R1441R; c.4323C > T) was detected in another PD case. Conclusions: In this brain bank-based series, LRRK2 G2019S mutation occurred in patients with parkinsonism associated with either typical brainstem LB pathology or non-specific nigral degeneration. LRRK2 mutations were not encountered in other neurodegenerative disorders associated with synuclein and tau deposition. (c) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:94 / 98
页数:5
相关论文
共 33 条
[31]   LRRK2 in Parkinson's disease and dementia with Lewy bodies [J].
Zhu, Xiongwei ;
Babar, Asim ;
Siedlak, Sandra L. ;
Yang, Qiwei ;
Ito, Genta ;
Iwatsubo, Takeshi ;
Smith, Mark A. ;
Perry, George ;
Chen, Shu G. .
MOLECULAR NEURODEGENERATION, 2006, 1 (1)
[32]   LRRK2 protein is a component of Lewy bodies [J].
Zhu, Xiongwei ;
Siedlak, Sandra L. ;
Smith, Mark A. ;
Perry, George ;
Chen, Shu G. .
ANNALS OF NEUROLOGY, 2006, 60 (05) :617-618
[33]   Mutations in LRRK2 cause autosomal-dominant Parkinsonism with pleomorphic pathology [J].
Zimprich, A ;
Biskup, S ;
Leitner, P ;
Lichtner, P ;
Farrer, M ;
Lincoln, S ;
Kachergus, J ;
Hulihan, M ;
Uitti, RJ ;
Calne, DB ;
Stoessl, AJ ;
Pfeiffer, RF ;
Patenge, N ;
Carbajal, IC ;
Vieregge, P ;
Asmus, F ;
Müller-Myhsok, B ;
Dickson, DW ;
Meitinger, T ;
Strom, TM ;
Wszolek, ZK ;
Gasser, T .
NEURON, 2004, 44 (04) :601-607